InsidersTradesSigma
Explore the detailed record of transactions filed by Dexter Susan, Chief Technology Officer. Officer active across 1 companies, notably Sonnet BioTherapeutics Holdings, Inc.. Cumulatively, 3 reports have been published. The latest transaction was disclosed on 25 May 2021 (Retenue fiscale). Regulator: SEC (Form 4). The full history is free.
3 of 3 declarations
Susan Dexter is the Chief Technical Officer at Sonnet BioTherapeutics Holdings, Inc. She is responsible for the company's technological initiatives, ensuring innovation and efficiency in processes. Her expertise in the biopharmaceutical field is crucial for the development of new therapies.